Cryoport, Inc. (NASDAQ:CYRX) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Cryoport, Inc. (NASDAQ:CYRX) have received a consensus recommendation of “Moderate Buy” from the seven analysts that are presently covering the company, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $12.29.

Several equities analysts recently issued reports on CYRX shares. Roth Mkm decreased their price target on Cryoport from $18.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, November 8th. Guggenheim began coverage on shares of Cryoport in a research report on Thursday, December 19th. They set a “buy” rating and a $11.00 target price on the stock. Finally, UBS Group lifted their price target on shares of Cryoport from $7.00 to $9.00 and gave the stock a “neutral” rating in a research report on Friday, October 18th.

Insiders Place Their Bets

In related news, CEO Jerrell Shelton sold 50,000 shares of Cryoport stock in a transaction that occurred on Thursday, November 21st. The stock was sold at an average price of $6.51, for a total value of $325,500.00. Following the transaction, the chief executive officer now directly owns 731,897 shares of the company’s stock, valued at $4,764,649.47. The trade was a 6.39 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ramkumar Mandalam sold 7,369 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $7.46, for a total transaction of $54,972.74. Following the completion of the transaction, the director now owns 59,497 shares in the company, valued at $443,847.62. This trade represents a 11.02 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 109,869 shares of company stock valued at $735,673. 10.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Cryoport

Institutional investors and hedge funds have recently modified their holdings of the business. Bank of New York Mellon Corp raised its stake in Cryoport by 13.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 169,155 shares of the company’s stock worth $1,169,000 after buying an additional 19,803 shares during the period. Rhumbline Advisers raised its position in shares of Cryoport by 3.4% during the second quarter. Rhumbline Advisers now owns 64,158 shares of the company’s stock worth $443,000 after purchasing an additional 2,086 shares during the period. Quest Partners LLC lifted its holdings in shares of Cryoport by 1,083,000.0% in the 2nd quarter. Quest Partners LLC now owns 10,831 shares of the company’s stock worth $75,000 after purchasing an additional 10,830 shares in the last quarter. NRI Wealth Management LC acquired a new stake in Cryoport in the 2nd quarter valued at $132,000. Finally, Federated Hermes Inc. bought a new stake in Cryoport during the 2nd quarter valued at $774,000. 92.90% of the stock is currently owned by institutional investors.

Cryoport Stock Down 0.9 %

NASDAQ:CYRX opened at $7.78 on Friday. The company has a market cap of $384.57 million, a price-to-earnings ratio of -2.30 and a beta of 1.62. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.32 and a current ratio of 5.70. The stock’s fifty day moving average price is $7.49 and its two-hundred day moving average price is $7.85. Cryoport has a 52-week low of $5.32 and a 52-week high of $20.10.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.